Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance to Refine Clinical Management Strategies

Learn how experts leverage BTK inhibitors for optimal management of patients with MCL, CLL, and other B-cell malignancies in this CME-certified, on-demand Webcast of a dynamic CCO symposium at ASH 2019.
Ian W. Flinn, MD, PhD
Program Director
Jan A. Burger, MD, PhD
Alexey Danilov, MD
John Pagel Headshot
John Pagel, MD, PhD
Released: February 4, 2020 Expiration: No longer available for credit

Related Content

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Gain key clinical insights from Sagar Lonial, MD on anti-BCMA ADCs for R/R MM, from Clinical Care Options (CCO)

Sagar Lonial, MD Released: September 10, 2021

Gain key clinical insights from Suzanne Lentzsch, MD, PhD on anti-BCMA bispecific antibodies for R/R MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Gain key clinical insights from Thomas G. Martin, MD on anti-BCMA CAR T-cell therapy for R/R MM, from Clinical Care Options (CCO)

Thomas G. Martin, MD Released: September 10, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue